Alimera Sciences Inc (NASDAQ:ALIM)

4.59
Delayed Data
As of Mar 27
 +0.21 / +4.79%
Today’s Change
4.12
Today|||52-Week Range
8.36
-17.15%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$203.6M

Company Description

Alimera Sciences, Inc. is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. It focuses on diseases affecting the back of the eye, or retina. Its primary product, ILUVIEN, for the treatment of vision impairment associated with chronic diabetic macular edema considered insufficiently responsive to available therapies. Alimera Sciences was founded on June 4, 2003 by C. Daniel Myers and David R. Holland and is headquartered in Alpharetta, GA.

Contact Information

Alimera Sciences, Inc.
6120 Windward Parkway
Alpharetta Georgia 30005
P:(678) 990-5740
Investor Relations:

Employees

Shareholders

Mutual fund holders7.87%
Individual stakeholders53.85%
Other institutional42.84%

Top Executives

Charles Daniel MyersPresident, Chief Executive Officer & Director
Richard S. EiswirthSecretary, Chief Operating & Financial Officer
Kenneth GreenChief Scientific Officer & Senior Vice President
Susan H. CaballaSenior VP-Regulatory & Technical Affairs
David R. HollandSenior Vice President-Sales & Marketing

To view my watchlist

Not a member yet?

Sign up now for a free account